A dual GLP-1/glucagon agonist developed in China showing competitive weight loss results in Asian populations.
Mazdutide (IBI362) is a dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics (China) in collaboration with Eli Lilly. It is an oxyntomodulin (OXM) analog — oxyntomodulin being a naturally occurring gut hormone that activates both GLP-1 and glucagon receptors.
Like survodutide and pemvidutide, mazdutide combines GLP-1-mediated appetite suppression with glucagon-driven energy expenditure and liver fat oxidation. Its development has been primarily focused on the Chinese and broader Asian markets, where obesity and metabolic disease are rapidly increasing.
Mazdutide is in Phase 3 trials in China for obesity and type 2 diabetes, with global development planned. It represents the expanding pipeline of dual and triple agonists following tirzepatide's commercial success.
Phase 2 results in Chinese populations showed up to 14.4% weight loss at 24 weeks with the 9 mg dose. HbA1c reductions in type 2 diabetes patients were clinically significant. Liver fat reduction was also observed, consistent with the glucagon component.
Phase 3 trials (GLORY program) are ongoing in China. Global expansion is planned. The drug may reach Asian markets before US/EU markets.
📚 Key Reference: PMID: 37482085 (mazdutide Phase 2)
GI side effects typical of GLP-1 class. Preliminary safety profile consistent with dual GLP-1/glucagon agonism. Full safety characterization pending Phase 3.
NOT FDA-approved. In Phase 3 trials primarily in China. Not available outside clinical trials.